Issue 8, 2014

Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

Abstract

The mammalian O-GlcNAc hydrolase (OGA) removes O-GlcNAc from serine and threonine residues on intracellular glycoproteins. OGA activity is sensitive to N-acyl substitutions to O-GlcNAc, with alkyl diazirine-modified O-GlcNAc (O-GlcNDAz) being completely resistant to removal by OGA. Using homology modeling, we identified OGA residues proximal to the N-acyl position of O-GlcNAc substrate. Mutation of one of these residues, C215, results in mutant enzymes that are able to hydrolytically remove O-GlcNDAz from a model compound. Further, the C215A mutant is capable of removing O-GlcNDAz from a peptide substrate. These results can be used to improve metabolism of O-GlcNAc analogs in cells. In addition, the enzyme specificity studies reported here provide new insight into the active site of OGA, an important drug target.

Graphical abstract: Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

Supplementary files

Article information

Article type
Concise Article
Submitted
10 Apr 2014
Accepted
30 May 2014
First published
02 Jun 2014

Med. Chem. Commun., 2014,5, 1227-1234

Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

A. C. Rodriguez and J. J. Kohler, Med. Chem. Commun., 2014, 5, 1227 DOI: 10.1039/C4MD00164H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements